PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management
Affiliation
Department of Histopathology and Molecular Pathology, St James's University Hospital, Leeds, UKIssue Date
2021
Metadata
Show full item recordAbstract
Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic programmed cell death ligand-1 (PD-L1) testing, previously established at our center for lung and bladder tumors, was undertaken in a few head and neck cancer cases. The scope of this study was to audit the relevant PD-L1 data and integrate the findings in our current clinical practice, with a view to promote improved routine laboratory biomarkers in HNSCC. Histopathology reports documenting tumor type, PD-L1 result and type of clone/assay were included in this study. Over a 5-year period, PD-L1 testing was undertaken in 199 cancer cases, including 3 with head and neck squamous carcinoma with low focal positive staining. Immunotherapy treatment in HNSCC demonstrates a discreet but still significant improvement in the overall survival of PD-L1 positive subjects.Citation
Bancu B, Cowan R, Chaturvedi A. PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT [Internet]. Vol. 8, Archive of Clinical Cases. Grigore T. Popa University of Medicine and Pharmacy; 2021. p. 14–8.Journal
Archive of Clinical CasesDOI
10.22551/2021.30.0801.10179PubMed ID
34754934Additional Links
https://dx.doi.org/10.22551/2021.30.0801.10179Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.22551/2021.30.0801.10179